Goldman Sachs analyst Corinne Johnson initiated coverage of TG Therapeutics (TGTX) with a Neutral rating and $37 price target The firm believes Briuvmi revenue growth will continue to be the key driver of the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX: